Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.

Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universi ties to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.